Rhythm Pharmaceuticals Wins FDA Approval for IMCIVREE in Acquired Hypothalamic Obesity Launch [Yahoo! Finance]
Rhythm Pharmaceuticals, Inc. (RYTM)
Last rhythm pharmaceuticals, inc. earnings: 3/8 08:12 am
Check Earnings Report
US:NASDAQ Investor Relations:
ir.rhythmtx.com
Company Research
Source: Yahoo! Finance
long-term in adults and pediatric patients aged 4 and older with acquired hypothalamic obesity, granting a broad label not limited to tumor-related hypothalamic injury and with no post-marketing commitments. Approval was supported by the global Phase 3 TRANSCEND program (full 142-patient dataset), which showed a statistically significant placebo-adjusted BMI reduction of at 52 weeks, and reported hunger improvements though hyperphagia was not included in the indication. Rhythm estimates roughly U.S. patients with acquired hypothalamic obesity (˜ incident cases/year), has expanded its U.S. field team to territory managers, and expects good payer coverage outside Medicare but warns that access, diagnosis logistics and Medicare policy could slow early uptake while pricing remains similar across indications. Interested in Rhythm Pharmaceuticals, Inc.? Here are five stocks we like better. 7 Stocks That Will Drive the Weight Loss Drugs Market Rhythm Pharmaceuticals (NASDAQ:RYTM) a
Show less
Read more
Impact Snapshot
Event Time:
RYTM
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
RYTM alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
RYTM alerts
High impacting Rhythm Pharmaceuticals, Inc. news events
Weekly update
A roundup of the hottest topics
RYTM
News
- How Investors May Respond To Rhythm Pharmaceuticals (RYTM) FDA Win For IMCIVREE In Acquired Hypothalamic Obesity [Yahoo! Finance]Yahoo! Finance
- Rhythm Pharmaceuticals EMANATE Phase 3 Misses Primary Endpoint, Sees Subgroup Signals for Setmelanotide [Yahoo! Finance]Yahoo! Finance
- Rhythm obesity drug wins broader use from FDA [Yahoo! Finance]Yahoo! Finance
- PANTHERx® Rare Selected by Rhythm Pharmaceuticals Inc. as the Exclusive U.S. Specialty Pharmacy for the Expanded Indication for IMCIVREE® (setmelanotide)PR Newswire
- Rhythm Pharmaceuticals (RYTM) Reports Phase 3 EMANATE Trial Topline Results for Setmelanotide [Yahoo! Finance]Yahoo! Finance
RYTM
Earnings
- 2/26/26 - Beat
RYTM
Sec Filings
- 3/20/26 - Form 8-K
- 3/16/26 - Form 8-K
- 3/16/26 - Form 4
- RYTM's page on the SEC website